Rubius Therapeutics, Inc. Common Stock (RUBY) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Create a list of the investments you want to track. Prior to Turnstone, Kris was with SQZ Biotech and was integral to a research partnership with Roche. Earlier in her career, Elhan spent more than a decade in Europe managing and leading investments in the healthcare sector at financial institutions such as BB Biotech-Bellevue Asset Management, Cantrade-UBS and Lombard Odier. While with Biogen, she served as attorney for the ex-U.S. launch of several products and provided legal oversight for the company’s manufacturing group, including a large-scale manufacturing facility construction project. Tamyra Toole joined Rubius in June 2018. From 2007 to 2009, Pablo was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas). Turnover per type of income can be broken down as follows: - Collaboration revenue (79.8%); - Grant revenue (20.2%). RUBIUS and RED PLATFORM are registered trademarks of Rubius Therapeutics, Inc. RUBIUS THERAPEUTICS, RED CELL THERAPEUTICS and RCT are trademarks of Rubius Therapeutics, Inc. All other trademarks referenced herein are the properties of their respective owners. All quotes are in local exchange time. Prior to joining Rubius, Spencer served as VP & Global Head of Cell & Gene Technical Development and Manufacturing at Novartis where he led the CMC development and manufacturing organization to deliver the CAR-T portfolio. Pepe joined Rubius Therapeutics as Chief Financial Officer in September 2020. While at Novartis, Spencer also led the process development teams in support of the commercialization of Cosentyx® and the registration and approval of ErelziTM and Rixathon®. This includes stock price, detailed quote, interactive chart, key metrics, and financials. He serves on the Board of Trustees for the Bay Area Discovery Museum and is a member of the Council on Foreign Relations. Lori Murray joined Rubius in 2018, and serves as the Chief Corporate Affairs Officer, leading internal and external communications, patient advocacy and corporate social responsibility. Year To Date Stock Performance calculation may combine companies, who have repoted financial results in different quarters. Maiken joined Rubius from Synlogic, Inc., where she served as general counsel. Rashmi began her career at Millennium Pharmaceuticals in Process Development Technology. Prior to joining Rubius, she served as an independent regulatory affairs consultant to biotechnology companies. She brings to Rubius more than 20 years of regulatory affairs and quality assurance experience in the biotechnology and pharmaceutical industry. in forensic science from Michigan State University. Rubius Therapeutics, Inc. (NASDAQ:RUBY) saw a large decline in short interest in March. Larry joined Rubius from Rheos Medicines, where he was a co-founder and served as Chief Scientific Officer. in Economics from Bogazici University in Istanbul, Turkey. Specifically, they have bought $498,885.00 in company stock and sold $40,833.00 in company stock. RUBY | Complete Rubius Therapeutics Inc. stock news by MarketWatch. Thursday the stock has been traded at … In 2020, Gilead Sciences secured an exclusive option to acquire Tizona for up to $1.5 billion. Greg received his B.S. All the shares in the offering are to be sold by Rubius. in nursing from Villanova University and a J.D. Rubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. Before joining venture capital, Larry spent 30 years working in academia, most recently serving as the Harold and Ellen Danser Professor of Surgery and Professor of Medicine at Harvard Medical School and Massachusetts General Hospital. Additionally, Dwight is listed on seven patents and has received numerous grants and awards throughout his career. We would like to show you a description here but the site won’t allow us. Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. Under his leadership, he established a culture of quality dedicated to patient safety and data integrity. Only 1.56% of the stock of CACI International is held by insiders. Theo holds a MBA in Marketing & Management, a M.S. Lori holds an MBA from the University of San Francisco and a B.A. Subscriber Agreement & Terms of Use, Larry was also an early leader in the field of T cell costimulation and contributed to the development of abatacept and belatacept for the treatment of rheumatoid arthritis and renal transplantation. Kris Elverum joined Rubius as Senior Vice President of Business Development and Strategy in July 2019, to develop the Company’s corporate strategy and create and execute new business development opportunities. in Biology from Eastern Nazarene College. in business administration from Bryant College. Have Watchlists? He is a former President of the American Society of Transplantation, Chair of the NIAID Board of Scientific Counselors and Editor in Chief of The Journal of Clinical Investigation. For the best MarketWatch.com experience, please update to a modern browser. We are proud of the passionate, high-performance culture we have built at Rubius Therapeutics—a culture based on a set of values that are the cornerstone of who we are and how we hold ourselves and each other accountable. Maiken holds master of laws and bachelor of laws degrees from Kings College University of London. Tamyra holds a B.S. in mathematics and biology from Temple University. This browser is no longer supported at MarketWatch. She holds a Bachelor of Chemical Engineering from the University Department of Chemical Technology, University of Bombay, Mumbai, India, and a Ph.D. from the University of Minnesota. Earlier, she held positions at several pharmaceutical companies, including executive director of oncology clinical development at Novartis; international project team leader, early development at Morphotek, Inc.; and was an asset team leader in early clinical development at Pfizer’s Oncology Business Unit. Prior to Novartis, he led manufacturing and CMC functions in support of Somavert®, Elonva®, Retavase® and Puregon® while at Merck, formerly Schering Plough, Organon and Covance. At Radius Health, he was responsible for all financial aspects of the business as well as investor relations, business development and other operational functions. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology. Prior to working in drug development, Tamyra held various positions in the Department of Nursing at Brigham and Women’s Hospital. He also led critical initiatives, including regulatory interactions and the successful transition from clinical to commercial production upon product approval. Under Pepe’s leadership, Radius Health was transformed from a clinical-stage company to a fully commercial organization. She holds an M.D. Joanne brings to Rubius more than 25 years of experience in finance and accounting, including 18 years in senior management roles in publicly traded companies. Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Before entering the pharmaceutical industry, Dr. Coughlin was an instructor in pediatrics at the University of Pennsylvania School of Medicine; completed her postdoctoral research fellowship in the Translational Research Group of the Abramson Family Cancer Research Institute under the direction of CAR-T cell therapy pioneer Carl June, M.D.